News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ruthigen To Hold Fiscal First Quarter 2015 Financial Results Conference Call On Thursday, August 14, 2014



8/8/2014 8:20:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SANTA ROSA, Calif., Aug. 7, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN) today announced that the financial results for its fiscal first quarter 2015, ended June 30, 2014, will be released after the U.S. markets close on August 14, 2014. The earnings release will be followed by a conference call at 1:30 p.m. PDT (4:30 p.m. EDT) on August 14, 2014, to discuss fiscal first quarter 2015 results.

Individuals interested in participating in the conference call may do so by dialing 1-877-870-4263 for domestic callers or 1-412-317-0790 for international callers. Those interested in listening to the conference call live via the internet may do so at http://www.videonewswire.com/event.asp?id=100276. Please log on approximately 30 minutes prior to the presentation in order to complete the registration process.

A telephone replay will be available for seven days following the conclusion of the call by dialing 877-344-7529 for domestic callers, or 412-317-0088 for international callers, and entering conference code 10051099. A webcast replay will be available on the site at http://www.videonewswire.com/event.asp?id=100276 for one year following the call.

About Ruthigen
Ruthigen is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications.  The Company's lead drug candidate, RUT58-60, is a broad-spectrum anti-infective containing a new formulation of hypochlorous acid, HOCl, with small molecule stabilizers that Ruthigen is developing for the prevention and treatment of infection in surgical and trauma procedures.  RUT58-60 uses a mechanism of action designed to prevent emergence of bacterial resistance and improves patient safety by neither targeting specific bacterial cell membrane receptors nor exposing patient's vital organs to unnecessary systemic drugs.  The Company plans to complete its Phase I/II clinical trial in Q1 2015 and pending the successful completion of that trial, Ruthigen plans to conduct pivotal clinical trials.  The Company's clinical program targets an initial $700M potential market in the prevention of infections associated with abdominal surgery.  The Company believes the market for prevention of infection in the U.S. surgical market is estimated at $3B.  For more information, visit www.ruthigen.com.

SOURCE Ruthigen, Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Ruthigen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES